Stock data
Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of US$291.85M and net income of US$0.55M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$291.85M | — | US$24.90M | US$0.55M | — |
| 2024 | US$203.07M | — | -US$33.65M | -US$54.84M | — |
| 2023 | US$163.91M | — | -US$44.01M | -US$62.26M | — |
| 2022 | US$110.25M | — | -US$81.94M | -US$94.66M | — |
| 2021 | US$49.59M | — | -US$115.16M | -US$122.72M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$92.10M | -US$31.10M | — |
| 2026-03-31 | US$83.13M | US$2.23M | — |
| 2025-12-31 | US$85.81M | US$11.08M | — |
| 2025-09-30 | US$74.38M | US$0.62M | — |
| 2025-06-30 | US$71.54M | -US$1.93M | — |
| 2025-03-31 | US$60.12M | -US$9.22M | — |
| 2024-12-31 | US$60.10M | -US$5.11M | — |
| 2024-09-30 | US$54.27M | -US$15.74M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.